Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Regulatory Changes Key To Life Sciences Investment Decisions – BioMedical Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Regulatory reforms during the next several years will help define the next generation of winners and losers in the China life sciences industry, and investors are anxiously parsing the landscape for any signals of how the changes might play out. But trying to predict what will come next out of a notoriously opaque regulatory process is an ongoing challenge for venture capitalists and bankers alike, as evidenced by a panel discussion on Chinese investment opportunities held March 18 during the annual BioMedical Asia conference in Singapore

You may also be interested in...



Wuxi And Qiagen Form Biomarker Partnership In Shanghai

SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases

Wuxi And Qiagen Form Biomarker Partnership In Shanghai

SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases

Medical Device Sector Expected To Gain The Most From China’s Healthcare Reform

SHANGHAI- China's medical device market has reached RMB 83 billion ($12.1 billion), roughly one-eighth of the total healthcare industry, according to a report by Frost & Sullivan

Related Content

UsernamePublicRestriction

Register

CO234398

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel